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Purpose of the study
The objective of this study is the evaluation of long-term
viral efficacy, liver enzyme safety and metabolic profile
during nevirapine plus nucleoside reverse transcriptase
inhibitor treatment.
Methods
In this open-label observational study, 120 (75 male and
45 woman) HIV-1 infected patients received a nevirapine
(NVP)-containing HAART regimen: first-line, simplifica-
tion or switch due to intolerance to the prior regimen.
Summary of results
Mean duration of therapy in the patients with NVP regi-
men at the recruitment was 7.3 ± 1.9 years. Forty-three
patients (35.9%) were antiretroviral-naïve: mean HIV-
RNA level was 50,000 copies/ml (range 2,000–214,000)
and mean CD4 cells count was 386 cell/mm3 (11–976).
Seventy-seven patients (64.1%) switched to NVP for sim-
plification or intolerance: mean viral load was 100,000
copies/ml (range 49–>500,000) and mean CD4 cells
count was 450 cell/mm3 (30–1,600). Baseline character-
istics included liver enzymes (ALT 31.6, AST 41.2 and
GGT 23.4) and fasting lipid profile (total cholesterol
202.4, HDL-cholesterol 59.17, LDL-cholesterol 131.4 and
triglycerides 210.7). Co-infection with hepatitis C viruses
were present in 25 (20.8%) patients. The efficacy and tol-
erability were evaluated at three time points for analysis:
baseline, at 2 years, and at 4 years after baseline.
At the last measurement, all patients had undetectable
viral loads (<50 copies/ml) and the mean CD4 cells count
increased from baseline values by 340 cells/mm3. In
naïve patients viral loads decreased during the first 6
months (range 3–9 months).
Throughout follow-up ALT (mean value 33,8 U/l) and
AST (mean value 39.1 U/l) remained within standard nor-
mal range. Mean value of GGT increased from the base-
line (mean value 57.04 U/l); p < 0,01). Total cholesterol,
HDL-cholesterol, LDL-cholesterol and triglycerides levels
at the second years and at the fourth years remained in
normal range in patients who switched to NVP for simpli-
fication or intolerance. Significant differences were found
in total cholesterol levels in antiretroviral-naïve patients
with increased value from the baseline to the last measure-
ment (p = 0.01).
Conclusion
The follow-up results showed that prolonged treatment
with NVP is a safe and potent antiretroviral regimen asso-
ciated with viral suppression and increased CD4 cells
count. In our patients the long-term exposure to NVP
showed an increased total cholesterol (not requiring use
of statins) and, in concordance with previous studies, an
increased GGT level essentially in patients co-infected
with HCV.
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